FDA OKs first pill in U.S. to reduce hay-fever allergies - 8 News NOW

'Ah-choo': FDA OKs first pill to reduce hay-fever allergies

Posted: Updated:
  • Paula's Health NotesLas Vegas Health NewsMore>>

  • Prostate frozen lumpectomy offers patients an alternative

    Prostate frozen lumpectomy offers patients an alternative

    Monday, July 28 2014 3:00 PM EDT2014-07-28 19:00:33 GMT
    More than 230,000 men will be diagnosed with prostate cancer this year according to the American cancer society. In most cases, surgical removal of the gland is considered the gold standard of treatment, but results of a new study suggest a new treatment might benefit some patients.More>>
    More than 230,000 men will be diagnosed with prostate cancer this year according to the American cancer society. In most cases, surgical removal of the gland is considered the gold standard of treatment, but results of a new study suggest a new treatment might benefit some patients.More>>
  • New therapies for epilepsy

    New therapies for epilepsy

    Friday, July 25 2014 3:00 PM EDT2014-07-25 19:00:14 GMT
    pilepsy is a chronic neurological condition that affects more than 2.5 million Americans. Uncontrollable seizures plague these patients’ lives. Until now, the only treatments were drugs and major surgery, but new therapies are on the horizon.More>>
    pilepsy is a chronic neurological condition that affects more than 2.5 million Americans. Uncontrollable seizures plague these patients’ lives. Until now, the only treatments were drugs and major surgery, but new therapies are on the horizon.More>>
  • Study touts health care workers with less than bachelor's degree

    Study touts health care workers with less than bachelor's degree

    Thursday, July 24 2014 12:08 AM EDT2014-07-24 04:08:05 GMT
    Among Las Vegas workers with less than a bachelor’s degree only 3.5 percent hold jobs in the most common health care occupations, the lowest percentage among the nation’s 100 largest metropolitan areas, the Brookings Institution reported Wednesday night.More>>
    Among Las Vegas workers with less than a bachelor’s degree only 3.5 percent hold jobs in the most common health care occupations, the lowest percentage among the nation’s 100 largest metropolitan areas, the Brookings Institution reported Wednesday night.More>>

TRENTON, N.J. (AP) -- The Food and Drug Administration said Wednesday that it has approved the first tablet in the U.S. for gradually reducing hay fever symptoms, an alternative to months of weekly doctor visits for uncomfortable allergy-desensitizing shots.

Oralair was approved for patients ages 10 through 65. It's made by France's Stallergenes SA, a leader in immunotherapy medicines that dissolve under the tongue.

Oralair tablets are to be taken daily starting four months before grass pollen season to reduce allergic reactions to the five most common U.S. grass types: Kentucky bluegrass, orchard, perennial rye, sweet vernal and Timothy. It contains freeze-dried extracts from pollens of those grasses.

Meanwhile, drugmaker Merck & Co. of Whitehouse Station, N.J., expects an FDA ruling by midyear on its two experimental immunotherapy tablets, one for ragweed and one for grass pollen allergies. Merck is a leader in respiratory treatments, selling Claritin allergy pills and Nasonex allergy spray, multiple asthma inhalers and Singulair, a former $5 billion-a-year allergy and asthma pill now available as an inexpensive generic.

About 60 million Americans have hay fever, but fewer than 3 million are treated with allergy shots. Until now, their only other option was medicines to temporarily relieve sneezing, runny nose, congestion, watery eyes and itchy eyes and nose.

In patient testing over one grass pollen season, Oralair reduced symptoms and need for medication by 16 percent to 30 percent, versus dummy tablets.

Common side effects include throat irritation and mouth swelling. Severe allergic reactions, including life-threatening ones, are possible. For that reason, the first dose is given at a doctor's office, where the patient is watched for potential problems.

Oralair was approved in Europe in 2008 and is approved for sale in 31 countries, including Canada, Australia and Russia.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KLAS. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.